These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 16442212

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Methods of calculating prostate-specific antigen velocity.
    Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF.
    Eur Urol; 2007 Oct; 52(4):1044-50. PubMed ID: 17197071
    [Abstract] [Full Text] [Related]

  • 13. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
    Berger AP, Deibl M, Strasak A, Bektic J, Pelzer AE, Klocker H, Steiner H, Fritsche G, Bartsch G, Horninger W.
    Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
    Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, D'Amico AV.
    Cancer; 2008 Aug 15; 113(4):717-22. PubMed ID: 18615505
    [Abstract] [Full Text] [Related]

  • 17. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.
    Prog Urol; 2009 Jul 15; 19(7):487-98. PubMed ID: 19559380
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
    Connolly D, Black A, Murray LJ, Nambirajan T, Keane PF, Gavin A.
    BJU Int; 2008 Jun 15; 101(12):1507-12. PubMed ID: 18341627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.